4th Quarter - Report

CONSTANTINE CANNON, LLP for AMERICA'S SPECIALTY MEDICINE COMPANIES (COMPRISED OF PARTICIPANTS ON LINE 13)

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

S. 27 -- patent settlements H.R. 1249, S. 23 -- patent reform

Foreign entity interest: S. 27 -- patent settlements H.R. 1249, S. 23 -- patent reform

LobbyistCovered position, as disclosed
STEPHEN S ANDERSON —
W STEPHEN CANNON —
DAVID D GOLDEN New —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 27 (112th), S. 23 (112th), H.R. 1249 (112th)

Health Issues HCR

S. 319 -- drug reimportation PDUFA reauthorization H.R.2632, S.1410 -- Life Sciences Jobs and Investment Act Orphan drugs H.R.2672, S.1423 -- Preserving Access to Orphan Drugs Act of 2011 H.R. 2 -- healthcare reform bill repeal Medicare rebates and reimbursement rates 340B drug discount program H.R.2674 -- 340B Program Improvement Act

Foreign entity interest: S. 319 -- drug reimportation H.R. 2 -- healthcare reform bill repeal PDUFA reauthorization; Life sciences research tax credit legislation Orphan drug issues H.R.2672, S.1423 -- Preserving Access to Orphan Drugs Act of 2011 H.R. 2 -- healthcare reform bill repeal Medicare rebates and reimbursement rates 340B drug discount program H.R.2674 -- 340B Program Improvement Act

LobbyistCovered position, as disclosed
STEPHEN S ANDERSON —
W STEPHEN CANNON —
DAVID D GOLDEN New —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2 (112th), S. 319 (112th), S. 1410 (112th), H.R. 2632 (112th), H.R. 2672 (112th), S. 1423 (112th), H.R. 2674 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.